1. Dynamic Effects of the Third Generation Bisphosphonate of Risedronate on Rat Osteoporotic Fractures for Clinical Usage Guidance
- Author
-
Dan Yang, Hao Ying, Hong-yun Li, Cheng-hui Ke, Jian Wang, Lin Wang, Hong-wen Zhu, and Jun Xu
- Subjects
Bone mineral content (BMC) ,medicine.medical_specialty ,Primary osteoporotic fracture (p‐OPF) ,Callus formation ,Ovariectomy ,medicine.medical_treatment ,Osteoporosis ,Urology ,Bone healing ,Bone tissue ,Risedronate (RD) ,Rats, Sprague-Dawley ,Bone Density ,medicine ,Animals ,Orthopedics and Sports Medicine ,Biomechanics ,Research Articles ,Fracture Healing ,Bone mineral ,Orthopedic surgery ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Femoral fracture ,Bisphosphonate ,medicine.disease ,Rats ,medicine.anatomical_structure ,Bone Trabeculae ,Female ,Surgery ,business ,Femoral Fractures ,Risedronic Acid ,Bone mineral density (BMD) ,Osteoporotic Fractures ,RD701-811 ,Research Article - Abstract
Objective To better understand the risks of bisphosphonates in order to develop guidance for appropriate clinical usage, to compared femoral fracture healing at different time points and to explore the effects of Residronate on fracture healing. Methods Osteoporosis model was achieved by ovariectomy surgery, followed by surgical incision of left femoral shaft 4 weeks after ovariectomy surgery. Three days after fracture surgery, risedronateor saline was fed by intragastric administration. X ray examination was used to check the callus formation, Bone Mineral Density (BMD), Bone Mineral Content (BMC), biomechanical, imaging and micromorphological of bone tissue as well as the trabecular bone parameters were all examined. The femoral pathology tissue of each rat was used to analyze trabecular bone parameters, including trabecular bone volume/tissue volume (Tb. BV/TV), bone surface to tissue volume ratio (BS/TV), trabecular bone mineral density (Tb. BMD), trabecular bone number (Tb. N), trabecular bone thickness (Tb. Th) and small bone Trabecular bone space (Tb. Sp). Results Via X‐ray and pathologically, risedronate treatment promoted the callus forming at the fracture site during the following 6 weeks after osteoporotic fracture by X‐ray (P, Using a rat osteoporotic model and controls we compared femoral fracture healing at different time points to explore the effects of Residronate on fracture healing at different time points measured: (i) via x‐ray and pathologically; (ii) through evaluation of bone mineral density and bone mineral content; and (iii) through load testing. Our results demonstrate that Risedronate could promote fracture healing at the first 3 weeks but delayed healing at the following 3 weeks. During the first 3 weeks, risedronate could obviously increase the BMD, decrease the BMC and delay the decrease of BMC of the fracture site. During the healing process of osteoporotic fracture rats, risedronate can improve the structural strength and mechanical index of newborn callus. It strongly recommends that longer than 7 weeks usage of third generation bisphosphonate of risedronate does not contribute to osteoporotic fracture.
- Published
- 2021